Abstract: Hepatocellular carcinoma (HCC) is usually detected late, in patients with advanced disease, who are thus not eligible for radical therapy. Despite this grim scenario, new treatment options for intermediate to advanced stages hold great promise, such as internal radionuclide therapy. Several techniques have been developed for radionuclide therapy of HCC. Among these, use of transarterial injection of a radiolabelled embolizing agent, such as microspheres or Lipiodol, has led to very encouraging results. Over the last few years, efforts to label Lipiodol with rhenium-188, an attractive beta-emitter, have led to a very active area of research. Lipiodol has been labelled either directly or by solubilisation of a lipophilic 188 Re-labelled complex. Preliminary clinical findings indicate the feasibility of using 188 Relabelled Lipiodol, which has shown good tolerance and good response rates in the treatment of unresectable HCC as well as in adjuvant or neo-adjuvant settings.
INTRODUCTION
Primary liver cancers, 75 % of which are hepatocellular carcinoma [1, 2] , are among the most common tumours worldwide. In terms of mortality, HCC ranks second in cancer-related deaths worldwide for men [3] . China accounts for half of the number of cases and deaths. In the vast majority of cases, HCC develops on an underlying liver disease, mostly cirrhosis, whose nature varies according to geographical region or ethnic group. 73.4 % of HCC cases are attributable to hepatitis B virus (HBV) and hepatitis C virus (HCV) [4, 5] . In India, for instance, 70 % to 80 % of all HCCs are related to HBV, approximately 15 % are related to HCV, and 5 % to both HBV and HCV. Alcohol alone accounts for approximately 8 % of all HCCs; in about 10 %, no direct etiology is seen. Iron overload and aflatoxin may also have a role in some geographical areas in India [6] . On the contrary, in Japan, HCV-related HCCs are predominant [7] . In Western countries, the main risk factors are alcohol and non-alcoholic fatty liver diseases, such as obesity and diabetes [8] , though an increase in HCV is to be noticed [9] . HCC prognosis remains very poor, despite a large range of treatment options [10, 11] . The heterogeneity in terms of aetiology and underlying disease further complicates the management of HCC. Treatment decisions are complex and dependent upon tumour staging, presence of portal hypertension, and the underlying degree of liver dysfunction, as well as local expertise, as indicated by the National Comprehensive Cancer Network (NCCN), Asian Pacific Association for the Study of the Liver (APASL), American Association for the Study of Liver (AASLD), Barcelona-Clinic Liver Cancer (BCLC), European Association for the Study of the Liver (EASL), and Italian Association of Study of the Liver (AISF) guidelines [9] (Figure 1 ). Due to generally late detection and pre-existing hepatopathy, 5-year survival is less than 5 %, and curative treatments, such as surgical resection or liver transplantation, are usually not possible. Less than 25 % of patients are candidates for these treatments. Furthermore, even for such patients, recurrence rates are high (10 to 40 % for transplantation and up to 50 % at 2 years for resection) [12] . For the vast majority of patients not eligible for curative treatments, liverdirected therapies can be proposed [13] . Until now, no systemic treatment has shown real effectiveness [14] . Progresses in external beam radiotherapy methods have recently improved the efficacy and tolerance of this technology for liver cancers [15, 16] , but the method is still not considered as a standard of care.
HCC being a richly vascularised tumour, mainly irrigated via the hepatic artery, while the healthy liver is supplied at 80 % by the portal vein, intra-arterially delivered treatments, such as transarterial chemoembolisation (TACE) and transarterial radioembolisation (TARE), represent two promising therapeutic approaches for patients without an advanced form of HCC. Currently, the most widely used treatment involves TACE coupled with intra-arterial injection of an emulsion of Lipiodol and a chemotherapeutic drug, followed by the occlusion of the feeding artery. TACE is currently considered as the standard of care for intermediate stage HCCs, achieving partial response in 20-50 % of patients and an expansion of median survival for up to 20 months [17] , but its therapeutic efficacy is still disputed.
Though not yet fully integrated into treatment decision schemes, transarterial radioembolisation, or selective internal radiation therapy (SIRT), is one of the most promising treatment modalities for intermediate stage HCCs [18, 19] . This strategy consists in the selective delivery of radiation directly to the tumour cells, while preserving healthy liver and minimizing systemic irradiation. Various materials (Lipiodol, glass, resin or polymer microspheres) and various radioisotopes have been used. The radioisotopes used in these preparations are beta-emitters, such as 166 Ho, 131 Lipiodol is a mixture of iodinated ethyl esters of poppy seed oil, which contains approximately 38 % iodine by weight and has been used as a CT contrast agent and as a carrier for TACE. When injected through the hepatic artery, it has been shown to be selectively trapped in tumour cells (HCC and some hepatic metastases) and to display prolonged retention within the tumour [20, 21] . Historically, Lipiodol was first labelled with iodine-131, by exchange with "cold" iodine [22] , with encouraging results in HCC management [23, 24] . However, the high energy gamma emission and long half-life of iodine-131 (E βmax = 0.81 MeV; Eγ = 364 keV (81 %); t 1/2 = 8.02 d), as well as its high production cost have hindered its more widespread use. Yttrium-90, a pure beta-emitter (E βmax = 2.28 MeV; t 1/2 = 64.0 h, max tissue penetration = 12 mm) [25] , and rhenium-188 (E βmax = 2.12 MeV; Eγ = 155 keV (15 %); t 1/2 = 16.9 h, max tissue penetration = 11 mm) [26] have been proposed as an advantageous alternative to iodine-131. As highlighted in this special issue, rhenium-188 appears promising, and several approaches have been proposed to label Lipiodol with this isotope, some of them being under clinical evaluation. 
LIPIODOL RADIOLABELLING
Lipiodol labelling with iodine-131 is accomplished by simple isotopic exchange. This method is however not feasible for radiolabelling with rhenium-188, since a chelate is necessary to bind the metal. 188 Re attached to the covalently bound EDTB (N, N, N' , N'-tetrakis-(2-benzymidazolmethyl)-1,2-ethanediamine)chelate led to biodistribution results similar to 131 I-labelled Lipiodol, but the radiolabelling method was awkward, as it was difficult to achieve a reaction between the aqueous [ 188 Re]-perrhenate and the water-insoluble Lipiodol [27, 28] . A simpler and more elegant approach was then proposed by Jackson et al. [29] . This approach consists in the preparation of a strongly lipophilic rhenium complex, which would be then solubilised in strongly hydrophobic Lipiodol. The labelling is thus not attained through a covalent bond but through hydrophobic interactions. It is thus of prime importance that the rhenium complex possesses sufficient lipophilicity to be dissolved into the Lipiodol phase and sufficient stability to remain firmly trapped in this substance. Soon after, Jeong et al. proposed the first "labelling" of Lipiodol with rhenium-188 chelated by an N 2 S 2 ligand, 188 Re-TDD (2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol) [30] . The radiotracer had an insufficient retention, owing to a continuous elimination of the chelate, which was in equilibrium with a hydrosoluble cationic species, so the same authors developed long-chain alkyl derivatives (from C 8 to C 16 ) with improved uptake and retention [31] . The longer the alkyl chain, the more lipophilic the compound, and, hence, the stronger the hydrophobic interactions between the fatty chains of the chelate and Lipiodol. Accordingly, the 4-hexadecyl derivative ( 188 Re-HDD) seemed the most promising, especially when compared with 188 Re-TDD [32] . Indeed, its tumour retention was increased 1.8-fold in tumour-bearing rabbit models. However, one limitation of 188 Re-HDD/Lipiodol is its relatively low labelling yield, between 50 and 70 %, which reduces the opportunity to obtain the highest therapeutic activities. Subsequently, a more efficient labelling approach (78 % yield), by replacing the HDD kit (containing the HDD ligand, tin chloride, tartaric acid and mannitol) by an AHDD kit, in which the two sulphydryl groups of the dithiolate ligand are acetylated [33] . This protection enhances the ligand stability, without modifying the biodistribution pattern, as shown in mice, following injection through the tail vein, the final product being the same 188 Re-HDD/Lipiodol radioconjugate. More recently, the 188 Re-HDD complex was renamed 188 Re-HTDD, being more consistent with initial results with TDD, T standing for tetramethyl. A new HDD compound was then developed, without the four methyl groups [34] (Figure  2 ). This new compound showed a significantly higher extraction yield into Lipiodol with 90.2 ± 2.6 %. Biodistribution was however only investigated through intravenous injection in healthy mice, thus tumour uptake or even liver uptake was not assessed. Other N 2 S 2 chelates have also been developed and investigated for Lipiodol labelling with 188 Re (Figure 3) . ECD (ethyl cysteinate dimer), labelled with technetium99m, is well known as a brain perfusion agent. Labelled with rhenium-188, it has been proposed as a suitable compound to be solubilised in Lipiodol [35] . This radioconjugate was obtained with a radiochemical purity of over 94 % and an activity concentration ranging from 1 to 10 mCi per mL of Lipiodol, but no information was provided on the Lipiodol extraction yield. Following intra-arterial injection of 188 Re-ECD/Lipiodol in rats, the average tumour-to-liver ratio steadily decreased from 13.21 at 1 h to 6.84 at 48 h, with high lung uptake and high urinary extraction, due to the constant washout of the rhenium complex from Lipiodol. This can be explained by the fact that part of the chelate is rapidly converted to a water-soluble form and excreted through the urinary bladder, as already described with the 99m Tc-analogue. To minimise these drawbacks, Luo et al. more recently described the intratumoural administration of this radioconjugate [36] . In a 60-day survival study, they demonstrated an improved survival for treated rats compared to control group (62 % and 20 % respectively). Wang et al. proposed another chelate based on the TDD moiety, the NEMPTDD, replacing the long alkyl chain with a 4'-methyl-β-piperidinylethyl pendant arm [37] . (Figure 3 ) The radioconjugate was also based on a more stable rhenium-nitrido core, instead of the more classical rhenium-oxo core. The 188 ReN-NEMPTDD complex was obtained in high-yield (> 95 %) and was stable in vitro and quickly eliminated in vivo. It was used to label Lipiodol -with no information on the extraction yield -and subsequently injected into VX2 tumourbearing rabbits, with an estimated biological half-life of 12 h in the tumour. Another recently developed N 2 S 2 ligand is the MN-16ET, developed by Tang et al. [38] , in which the two sulphydryls of the dithiolate ligand are protected by triphenylmethyl groups and the lipophilic chain is an ethylhexadecanoate moiety. (Figure 3) This radioconjugate was assessed for its therapeutic efficacy [39] and compared to TACE in another animal study [40] . Rats treated with 188 Re-labelled Lipiodol showed increased survival and decreased tumour size compared to Lipiodol alone, or Lipiodol + epirubicine. As another key example, 188 ReN(DEDC) 2 (nitridobis-(diethyldithiocarbamato) rhenium), based on the more stable nitridorhenium core, was prepared with high yield (> 95 %) [41] and was almost quantitatively extracted in Lipiodol (96 %) . Biodistribution studies in non-tumour-bearing rats have shown promising results, with high uptake in the liver (2.3 % ID/g at 6 h), without prolonged retention due to the absence of tumour (0.3 % ID/g at 72 h). However, at high activities (7.7-12.0 GBq in 2.5 mL Lipiodol), there is a significant radiolysis of 188 ReN-DEDC/Lipiodol, which can be limited by dilution with cold Lipiodol.
Since rhenium (V) is easily reoxidised to rhenium (VII), rhenium-188 radioconjugates at lower oxidation states have been proposed to label Lipiodol. 188 Re-SSS [42] , a rhenium (III) complex, has been used to label Lipiodol with high yield and high radiochemical purity (> 90 %). This agent demonstrated very high in vivo stability and preferential tumour uptake in hepatomabearing rats [43] . Rhenium (I), based on a tricarbonyl core, was also proposed, but only described with rhenium-186 [44] . Even lower oxidation states have been proposed, since labelling of Lipiodol with elemental 188 Re, simply reduced from [ 188 Re]-perrhenate and without any chelating agenthas been described [45] .
The whole preparation involves different steps and complex manipulation of high activities of 188 Re that dramatically increases radiation exposure of the operator, particularly at the finger tips [46] . Automation of the process was therefore developed by several teams for their respective radioconjugates [47, 48] . Current advantages of automation include the elimination of the aqueous solvent and of any residual hydrophilic species such as [ 188 Re]-perrhenate, through a C18 Sep-Pak cartridge, sterilisation by passing the resulting solution through a 0.22 !m filter, thus complying with radiopharmacy standards, and, most of all, reduced operator assistance during the production process resulting in a dramatic reduction of radiation exposure [49] .
Direct comparison between the different radioconjugates is not possible, because different animals were used (rats, mice, rabbits and pigs), with or without tumour, and with different tumour strains (VX2, N1-S1) in the first case, or with different injection modalities (intra-arterial or intra-venous) in the second case.
CLINICAL RESULTS
In the last few years, transarterial metabolic radiotherapy has gained a central role in the management of patients with primary and metastatic liver malignancies [50, 51] . In particular, the efficacy of these locoregional radiation-based treatments has been demonstrated in HCC. A summary of clinical trials involving TARE in HCC management -with emphasis on radiolabelled Lipiodol -is given in Table 1 . The first agent to be developed has been 131 I-labelled Lipiodol, in the mid-80's [52, 53] . Very encouraging results with Phase III trials showed it was effective in patients with HCC and portal vein thrombosis (PVT) and in prevention of post-resection recurrence, and it was equivalent to chemoembolization in patients with HCC without PVT [24, 54] . However, its development was hindered by the characteristics of iodine-131. Indeed, beside its high production cost, iodine-131 has a long half-life and high-energy gamma emission, requiring a 7-day hospitalization in a radioprotection room. 90 Ymicrospheres, either glass or resin-based, are currently the most used modality for TARE [55] , but are prohibitively expensive, especially for low-income countries. In this context, rhenium-188 has a role to play, as it can be obtained at a lower cost thanks to its generator mode of production, could be used in an outpatient setting, like yttrium-90, but with the advantage of a low energy gamma emission, enabling visualisation of the injected tracer. Re-SSS [42] (Figure 4) . 188 Re-TDD/Lipiodol was the first agent to be investigated, in a pilot trial with one patient [56] , showing high thyroid and bowel uptake. It was quickly abandoned in favour of the more suitable 188 Re-HDD/Lipiodol, which had demonstrated significantly longer half-life and residence time. Indeed, based on estimated dosimetry in a rabbit liver cancer model [57] , it has been calculated that, for a 100 Gy tumour irradiation, a 1.85-GBq dose of 188 Re-TDD/Lipiodol would be necessary with a 5.27-cm tumour, while a 1.07-GBq dose of 188 Re-HDD/Lipiodol would be sufficient. Most studies up to now have been performed using 188 Re-HDD/Lipiodol. Preliminary findings by Keng et al. [58] in a small group of patients showed a stabilisation of the disease after treatment, but were not fully conclusive due to the small number of patients (5) and the limited period of follow-up (0.8-6.9 months). Under the auspices of the International Atomic Energy Agency (lAEA), a multicentre multination study was launched, including 70 patients over a period of 18 months [59] . 16 patients were treated in the dose escalation phase of the study, where the activities administered started at 1.8 GBq and rose to 7.7 GBq. In the efficacy phase of the study, a further 54 patients were treated. The treatment activity of 188 Re-HDD/Lipiodol ranged from 1.8 GBq to 9.8 GBq (mean activity 4.6 GBq), with some patients receiving up to four cures, for a cumulative dose of 25.6 GBq. Only moderate adverse events (mild anorexia, right hypochondrial discomfort, low-grade fever, 2 pleural effusions) were recorded in 35 out of 70 patients. Results were 13 progressions (PR), 34 stabilised disease (SD) and 23 disease progression (DP). Another dose-escalation study has been undergone by Lambert et al., in Ghent [60] , in 28 patients with well-compensated cirrhosis (Child A). Activities from 4.8 to 7.0 GBq were administered in 35 treatments without severe adverse events at all activities. Symptoms were reported in 19 out of 32 treatment sessions, and all organ dose estimates were below adverse radiation-induced effects. Treatment response was 1 PR, 28 SD and 2 DP. The authors also noticed high urinary excretion (44.1 ± 11.7 % within 76 h), for a calculated whole-body effective half-life of 14.3 ± 0.9 h [61] . In both studies, further escalation was not possible because of the low yields of 188 Re-HDD labelling [33] . A further escalation study with 188 ReLipiodol, with SSS as chelate, is currently going on (https://clinicaltrials.gov/show/NCT01126463), but results have not yet been published. Only preliminary results on pharmacokinetics have been described [62] , showing the high in vivo stability of the radiotracer, since only a faint -and mainly urinary -elimination occurs at 72 h (Figure 5) . In a preliminary study with DEDC as chelate [41] , including 11patients, treated with activities ranging from 2.5 to 5 GBq, no treatment related adverse events were noted. However, an additional patient, treated with 6 GBq of 188 Re-Lipiodol, developed grade IV myelosuppression, successfully treated with platelet transfusion and granulocyte colony-stimulating factor (GCSF) therapy. Activity escalation study by Lambert et al. [60] , was on Child A patients. The same team also reported a feasibility study on Child B patients, with advanced underlying cirrhosis [63] . 12 patients, 4 of which with portal vein thrombosis (PVT), were treated with a mean injected activity of 3.7 ± 0.2 GBq. Adverse events were reported for 6 patients in 2 weeks, with 3 patients dropping out of the study because of deterioration of their general condition. 7 patients had a stabilised disease, and 1 had a partial response and was subsequently transplanted. The conclusion of the study was that 3.7 GBq in the proper artery or both lobes was too aggressive and that supraselective injection might preserve liver function and enhance antitumoural activity.
Another feasibility study on dosimetry-guided treatment of patients with extensive PVT was reported on one patient with a large tumour extending in the right branch and main portal vein [64] . The patient was Child A status and had an HBV-related underlying cirrhosis and received 2 doses (4.29 + 4.17 GBq), based on dosimetry after injection of a scout dose of 188 Re-Lipiodol (185 MBq). The doses to the tumour were respectively 127 and 123 Gy. The authors noted a complete disappearance of tumour and thrombus after the 2nd injection. Unfortunately, the patient died of liver failure due to progression of his cirrhosis, after 14 months.
Phase II Study
Since preliminary results seemed promising, a Phase II trial was sponsored by the IAEA, including 185 patients from 8 countries, over a period of 5 years [65, 66] . Among these patients, 134 were treated only once, while 51 were treated up to 4 times. Total injected doses ranged from 0.78 to 13.45 GBq (including the scout dose used to calculate the patient specific dosimetry to critical organs). The mean administered dose was 4 GBq, representing a mean tumour absorbed dose of 63.4 Gy. Upon a median 455 days follow-up, findings were 25 % objective response (among which 3 % of complete response), 53 % stable disease and 22 % tumour progression. The 1-year survival reached 46 %, and 2-year survival was 23 %. Factors affecting survival were: country of origin, existence of a cirrhosis, CLIP score, tumour dose, absence of progression, and post-treatment decrease in α-Fetoprotein level. Overall, treatment was well tolerated, with less than 20 % severe adverse events. The authors therefore called for a phase-III clinical trial.
In the 93 patients from India and Vietnam, from the IAEA Phase II study, as reported by Kumar et al. [67] , mean activity was 5.3 ± 1.6 GBq which delivered 88 Gy to the tumour. Treatment was well tolerated and response rates were 33 % objective response (among which 8 % of complete response), 35 % stable disease and 32 % tumour progression. While overall survival rates at 6, 12, 24, and 36 months were 75 %, 50 %, 30 %, and 20 %, respectively, with a median survival of 356 days, corresponding survival rates among patients with objective tumour response were 100 %, 90 %, 58 %, and 30 %, with a median survival of 980 days.
Adjuvant and Neo-Adjuvant Treatments

131
I-Lipiodol has shown encouraging results as adjuvant treatment, with an increase in overall and disease-free survivals [68] . 188 Re-Lipiodol has thus been investigated for this indication. In 2006, one patient, with 2 small lesions in the left lobe after surgery, was administered one dose of 4.58 MBq of 188 Re-Lipiodol: 90 % of the activity (4.122 MBq) was injected selectively in the artery feeding the tumour, delivering 82.9 Gy of radiation dose to the tumour and 26.8 Gy to the normal liver parenchyma; while 10 % of the activity (458 MBq) was injected in the left hepatic artery, which, even if it had gone completely to the normal liver parenchyma, would have delivered 2.98 Gy of radiation to it, thereby keeping the total radiation to the normal liver parenchyma less than 30 Gy [69] .
Therapy was well tolerated, and the lesions were completely ablated with a single dose. The patient was disease-free for the time of follow-up (14 months); to compare to the 4-month median survival with postsurgical recurrences. Another patient with multiple intrahepatic recurrences after radiofrequency ablation was treated with an injection of 7.03 GBq, delivering 100.03 Gy to the tumour [70] . The patient remained disease-free 18 months after treatment (time of followup), without any adverse effect.
For patients awaiting liver transplantation, preliminary studies on intra-arterial injection of 131 Ilabelled Lipiodol have demonstrated encouraging results [71, 72] 188 Re compared favorably to 131 I, thanks to its shorter half-life. Patients were eligible for transplantation after only 1 week, as compared with the 4-week interval with 131 I, due to radioprotection issues.
These results advocate for larger trials, involving more patients.
DOSIMETRY
Main organs at risk in transarterial radionuclide therapy are liver (68 %), lungs (32 %) and bone marrow with their respective maximum-tolerated doses of: 30, 12 and 1.5 Gy. To avoid reaching these limits, and calculate the dose to the tumour, some authors used a scout dose of 188 Re-Lipiodol of 185 MBq and injected a patient-specific dosimetry-based therapeutic dose, while other used a fixed-activity dose. In their feasibility study with advanced cirrhotic patients, Lambert et al. administered a 3.7 ± 0.2 GBq 188 ReLipiodol dose in the hepatic artery to 12 patients; the absorbed doses to the liver, lungs, kidney, and thyroid were 7.6 ± 2.9, 4.8 ± 2.6, 0.8 ± 0.7, and 0.2 ± 0.1 Gy (mean ± SD), respectively [63] . 36.2 ± 5.7 % of the activity was excreted in the urine 52 h after injection. Moreover, the dose rate at 1 m was less than 20 µSv/h, enabling outpatient treatment.
Regarding the dose to the tumour, Bernal et al. found that a threshold dose of 30 Gy might lead to enhance survival [66] . Indeed, patients receiving a dose lower than 30 Gy (median 18Gy) had a median survival of less than 5 months, when patient receiving a higher dose than 30 Gy (median 56.8 Gy) had a median survival of 15 months. It has also been postulated that rhenium-188 might be more efficient for the treatment of small tumours of millimeter through centimeter dimensions, but would be relatively less effective in the treatment of very small micrometastases as well as larger macroscopic tumours [74] . A mathematical model determined the optimal diameter of the tumour to be 26 mm, to reach the maximal cure probability [75] .
Comparing the various therapeutic isotopes, rhenium-188 is said to be equal to or even superior to yttrium-90 or lutetium-177 [76] . In a rat liver dosimetry model, comparing 131 I, 90 Y, 188 Re and 166 Ho, the last two seem to be safer and more effective for radionuclide therapy of HCC compared to 131 I and 90 Y [77] .
In patients [78] , when compared with 131 I-Lipiodol, 188 Re-Lipiodol induces fewer cytotoxic effects and shows significantly lower total patient body doses (1.04 Gy vs. 1.46 Gy) for an expected higher tumour-killing effect. According to MIRDOSE calculations, 188 ReLipiodol and 131 I-Lipiodol may be expected to have the same biological effect on the tumour with an 188 Re activity 60 % higher than the 131 I activity.
Another important point concerning the dose to the tumour and the whole liver is the way to inject radiolabelled Lipiodol. Some authors [59] are in favour of a supra-selective injection, as close to the feeding artery as possible, while others [61] advocate for a nonselective injection. Advantage of the first modality would be a higher dose to the tumour and limiting dose to the healthy liver, but the second modality would enable the targeting of occult (metachronous) tumours, at the expense of an irradiation of non-tumorous tissues. This second approach should be reserved for patients with sufficient liver function.
FUTURE DEVELOPMENTS Combined Treatments
Combining treatment modalities could be a way to increase efficacy and/or decrease side effects, and appears to be highly attractive. In a clinical trial with 131 I-Lipiodol, combination with low dose cisplatin was shown to improve response rate compared to 131 ILipiodol alone, 90 % vs. 40 % respectively [79] . In a phase II trial, combination of 131 188 Re and sorafenib, a multikinase inhibitor, which is the goldstandard for advanced stage HCC [81] . In another study with HepG2 cells, a transient mild supra-additive effect was demonstrated with 5-FU, while no effect was obtained with topotecan or gemcitabine [82] . On the contrary, in cholangiocarcinoma (CCA) cells, gemcitabine increased the efficacy of 188 Re irradiation [83] . Interestingly, with yttrium-90, gemcitabine showed synergistic effect both for HCC and CCA cell lines, while oxaliplatin showed synergy only on CCA, and sorafenib and paclitaxel had antagonist effects in all cell lines [84] .
In hepatoma-bearing rats, it has been shown that pretreatment with dexamethasone and tamoxifen could lead to a significant increase (+ 44 %) in tumour uptake [85] .
Other Indications
Hepatocellular carcinoma is the main primary tumour of the liver, but other tumours may occur within the liver -either primary, such as cholangiocarcinoma (CCA) or metastases from various primary tumours [2] -and could be potential target for transarterial radionuclide therapy with 188 Re-Lipiodol. 90 Y-microspheres have been investigated with success in both primary and secondary liver tumours [55] . Lipiodol has shown predominant accumulation and longer retention in HCC and in hyperarterialyzed liver metastases, such as gastroenteropancreatic neuroendocrine tumours, and has thus been widely used in TACE in these indications [86] . TACE with Lipiodol has also been demonstrated to be safe and efficient in intrahepatic cholangiocarcinomas [87] , but similar data with 131 ILipiodol are scarce. Concerning CCA, results are contradictory. In a study including a large CCA patient, Risse et al. obtained a stabilisation of the disease [88] , while a pilot study including 8 CCA led to poor results, with only one CCA retaining 131 I-Lipiodol [89] .
Regarding metastases, in the same study, Risse et al. also treated one patient with multiple breast cancer metastases leading to significant reduction in number and size [88] . A case report on 131 I-Lipiodol treatment of renal cell carcinoma hepatic metastases also suggests a possible interest in this indication [90] . In vitro efficacy in colorectal metastatic cell lines was also demonstrated [91] . With all these preliminary results, 131 I-Lipiodol was thus not recommended for CCA therapy, but could be used for liver metastases [92] . Based on these data, 188 Re-Lipiodol could be of potential use for some of these indications. Clinical trials are therefore required to assess its interest.
CONCLUSIONS
There have been many methods under preclinical and clinical investigation to treat patients with secondary or primary liver cancer, and particularly hepatocellular carcinoma. Transarterial radionuclide therapy with 188 Re-Lipiodol is a relatively inexpensive, safe and a promising treatment for HCC. Preliminary encouraging findings have now to be confirmed in large randomised trials, being compared with other approaches, such as trans-arterial chemoembolization, 90 Y-microspheres and/or targeted therapies, to assess the place of 188 Re-Lipiodol in the therapeutic armamentarium. Future treatment strategies may rely on the combination of these modalities.
